Kindred Biosciences Inc. has made good on the planned release of its new transdermal medication for the management of unintended weight loss in cats.
The Northern California biopharmaceutical company reported July 11 that preorders for Mirataz (mirtazapine transdermal ointment) are being shipped to veterinarians and that additional orders may be placed through animal health product distributors.
The medication, which is applied to the inner pinna of a cat’s ear, earned approval from the U.S. Food and Drug Administration’s Center for Veterinary Medicine in May 2018.
“Mirataz gives veterinarians and their clients a practical way to manage feline weight loss without the need for administration of oral medication,” said Valentine S. Williams, DVM, MS, DACVS, the director of veterinary affairs at KindredBio. “Since it is applied topically, it does not depend on the cat’s willingness to eat to be medicated.”
Clinical studies showed that Mirataz “resulted in significant weight gain … in cats in as little as 14 days following topical application of 2 mg per day,” KindredBio stated.